Dyne Therapeutics financials
$16.21−0.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$181.7M | -$125.3M | -$116.1M | -$113.9M | -$115.8M | -$122.4M | -$97.1M | -$105.7M | -$72.0M | -$69.2M | -$67.7M | -$62.3M |
| Net income | -$178.6M | -$120.9M | -$112.0M | -$108.0M | -$110.9M | -$115.4M | -$89.5M | -$97.1M | -$65.1M | -$65.6M | -$66.6M | -$60.2M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.08 | $-0.73 | $-0.76 | $-0.76 | $-0.97 | $-1.05 | $-0.88 | $-0.96 | $-0.70 | $-0.81 | $-1.08 | $-0.99 |
| EBITDA | -$181.1M | -$124.7M | -$115.6M | -$113.4M | -$115.3M | -$121.9M | -$96.7M | -$105.2M | -$71.6M | -$68.8M | -$67.7M | -$61.8M |
| Operating cash flow | -$130.3M | -$144.9M | -$111.8M | -$90.8M | -$94.7M | -$105.9M | -$84.3M | -$74.6M | -$54.9M | -$78.5M | -$35.0M | -$50.6M |
| Free cash flow | -$131.8M | -$145.1M | -$112.3M | -$110.0M | -$94.8M | -$106.9M | -$85.4M | -$74.9M | -$55.7M | -$78.7M | -$35.1M | -$50.8M |
| Diluted shares | 165.5M | 165.0M | 148.2M | 141.8M | 113.9M | 109.9M | 102.1M | 100.9M | 92.5M | 81.0M | 61.5M | 61.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $676.1M | $753.1M | $893.4M | $573.6M | $485.0M | $472.3M |
| Short-term investments | $222.4M | $219.1M | $217.2M | $218.3M | $198.9M | $205.2M |
| Total debt | $213.5M | $155.6M | $148.9M | $99.1M | $98.8M | $0.00 |
| Total assets | $994.0M | $1.08B | $1.19B | $867.1M | $729.0M | $721.1M |
| Total liabilities | $291.9M | $214.9M | $214.8M | $175.3M | $157.5M | $52.1M |
| Shareholders' equity | $702.2M | $865.1M | $972.1M | $691.8M | $571.4M | $669.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology